{"EPA_reg_num": "6836-136", "Risk_level": "Increased Risk", "Active_ingredient": "[\"Quaternary ammonium\"]", "Product_name": "Lonza Formulation S-18F", "Company": "Arxada, LLC", "Use_site": "[\"Healthcare\", \"Institutional\", \"Residential\"]", "Surface_type": "[\"Hard Nonporous (HN)\"]", "Contact_time": 1.0, "Formulation_type": "[\"Dilutable\"]", "Follow_directions_for_this_virus": "SARS-CoV-2", "Date_on_List_N": "2021-04-13", "Why_on_List_N": "Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim", "ID": 1099}
{"EPA_reg_num": "6836-140", "Risk_level": "Increased Risk", "Active_ingredient": "[\"Quaternary ammonium\"]", "Product_name": "Lonza Formulation S-21F", "Company": "Arxada, LLC", "Use_site": "[\"Healthcare\", \"Institutional\", \"Residential\"]", "Surface_type": "[\"Hard Nonporous (HN)\"]", "Contact_time": 1.0, "Formulation_type": "[\"Dilutable\"]", "Follow_directions_for_this_virus": "SARS-CoV-2", "Date_on_List_N": "2021-04-13", "Why_on_List_N": "Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim", "ID": 1100}
{"EPA_reg_num": "6836-77", "Risk_level": "Increased Risk", "Active_ingredient": "[\"Quaternary ammonium\"]", "Product_name": "Lonza Formulation S-18", "Company": "Arxada, LLC", "Use_site": "[\"Healthcare\", \"Institutional\", \"Residential\"]", "Surface_type": "[\"Hard Nonporous (HN)\"]", "Contact_time": 1.0, "Formulation_type": "[\"Dilutable\"]", "Follow_directions_for_this_virus": "SARS-CoV-2", "Date_on_List_N": "2021-04-13", "Why_on_List_N": "Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim", "ID": 1102}
{"EPA_reg_num": "6836-381", "Risk_level": "Increased Risk", "Active_ingredient": "[\"Quaternary ammonium\"]", "Product_name": "Lonzagard R-82G", "Company": "Arxada, LLC", "Use_site": "[\"Healthcare\", \"Institutional\", \"Residential\"]", "Surface_type": "[\"Hard Nonporous (HN)\"]", "Contact_time": 1.0, "Formulation_type": "[\"Dilutable\"]", "Follow_directions_for_this_virus": "SARS-CoV-2", "Date_on_List_N": "2021-04-13", "Why_on_List_N": "Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim", "ID": 1103}
{"EPA_reg_num": "6836-139", "Risk_level": "Increased Risk", "Active_ingredient": "[\"Quaternary ammonium\"]", "Product_name": "Lonza Formulation R-82F", "Company": "Arxada, LLC", "Use_site": "[\"Healthcare\", \"Institutional\", \"Residential\"]", "Surface_type": "[\"Hard Nonporous (HN)\"]", "Contact_time": 1.0, "Formulation_type": "[\"Dilutable\"]", "Follow_directions_for_this_virus": "SARS-CoV-2", "Date_on_List_N": "2021-04-13", "Why_on_List_N": "Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim", "ID": 1104}
{"EPA_reg_num": "6836-75", "Risk_level": "Increased Risk", "Active_ingredient": "[\"Quaternary ammonium\"]", "Product_name": "Lonza Formulation S-21", "Company": "Arxada, LLC", "Use_site": "[\"Healthcare\", \"Institutional\", \"Residential\"]", "Surface_type": "[\"Hard Nonporous (HN)\"]", "Contact_time": 1.0, "Formulation_type": "[\"Dilutable\"]", "Follow_directions_for_this_virus": "SARS-CoV-2", "Date_on_List_N": "2021-04-13", "Why_on_List_N": "Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim", "ID": 1109}
{"EPA_reg_num": "6836-78", "Risk_level": "Increased Risk", "Active_ingredient": "[\"Quaternary ammonium\"]", "Product_name": "Lonza Formulation R-82", "Company": "Arxada, LLC", "Use_site": "[\"Healthcare\", \"Institutional\", \"Residential\"]", "Surface_type": "[\"Hard Nonporous (HN)\"]", "Contact_time": 1.0, "Formulation_type": "[\"Dilutable\"]", "Follow_directions_for_this_virus": "SARS-CoV-2", "Date_on_List_N": "2021-04-13", "Why_on_List_N": "Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim", "ID": 1110}